en · de · es · fr · pt
melanotan-2-notes.peptides4088.com › Guide › Background And Chemical Profile — Explained

Background And Chemical Profile — Explained

By Editorial Desk · published 2025-09-05 · last reviewed 2025-10-27 · Guide

MC1R comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-10-27. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Chemical Profile

Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.

Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.

Origins and Research Status

The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.

Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.

Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.

Melanotan-2 at a glance

PropertyValueNotes
Molecular classSynthetic cyclic heptapeptideAnalog of alpha-MSH with an internal lactam bridge
Molecular weightApproximately 1024 daltonsFree base value; salt forms differ
AppearanceWhite to off-white powderUsually supplied as a lyophilized solid
SolubilityFreely soluble in waterPoorly soluble in nonpolar solvents
Typical storage−20 °C, dry, protected from lightRepeated freeze-thaw cycles degrade peptides

Background and Receptor Mechanism

Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.

Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.

Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.

Related pages on this site

Identity and Chemical Background

Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.

Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.

Melanotan II Background and Mechanism

Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.

Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.

Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.

Chemistry and Receptor Pharmacology

Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.

Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.

Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.

Supporting material

=== Uplink and Uplink Redux === In 2012, mapper Michael "Hezus" Jansen created the mod Black Mesa: Uplink, a remake of Half-Life's demo level, Uplink. Jansen worked on the mod for three years before release, saying "I've recreated something people played 13 years ago, that means it's intertwined with nostalgic feelings." With the transition from mod to game in 2015, Jansen returned to the idea and started work on recreating it for the Steam version that featured new content and updated graphics called Black Mesa: Uplink Redux. However, in 2019, Jansen halted the production of the mod due to health issues.

Amphetamine is a potent psychostimulant of the phenethylamine class that is approved for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. Amphetamine is also used off-label as a performance and cognitive enhancer, and recreationally as an aphrodisiac and euphoriant. Although it is a prescription medication in many countries, unauthorized possession and distribution of amphetamine is often tightly controlled due to the significant health risks associated with uncontrolled or heavy use. As a consequence, amphetamine is illegally manufactured in clandestine labs to be trafficked and sold to users. Based upon drug and drug precursor seizures worldwide, illicit amphetamine production and trafficking is much less prevalent than that of methamphetamine. The first pharmaceutical amphetamine was Benzedrine, a brand of inhalers used to treat a variety of conditions. Because the dextrorotary isomer has greater stimulant properties, Benzedrine was gradually discontinued in favor of formulations containing all or mostly dextroamphetamine. Presently, it is typically prescribed as mixed amphetamine salts, dextroamphetamine, and lisdexamfetamine. Amphetamine is a norepinephrine–dopamine releasing agent (NDRA). It enters neurons through dopamine and norepinephrine transporters and facilitates neurotransmitter efflux by activating TAAR1 and inhibiting VMAT2. At therapeutic doses, this causes emotional and cognitive effects such as euphoria, change in libido, increased arousal, and improved cognitive control.

== Playwrights == Peter Barnes, playwright Steven Berkoff, playwright, actor, author, and theatre director Ashley Blaker, comedian and television producer; writer for TV and radio and longtime collaborator with Matt Lucas: was producer of Little Britain and Rock Profile. Lucas described Blaker as "the UK's only Orthodox comedian". Blaker's Off-Broadway show, Strictly Unorthodox, opened in 2017 at The Theater Center. and his second Off-Broadway show, Goy Friendly opened in February 2020, at SoHo Playhouse. Ben Elton (born 3 May 1959) comedian, actor, author, playwright, lyricist and director; was a part of London's alternative comedy movement of the 1980s and writer on the sitcoms The Young Ones and Blackadder, as well as stand-up comedian on stage and television; style in the 1980s was left-wing political satire; Elton is cousin of singer Olivia Newton-John; Elton's father is from a German-Jewish family and Elton's mother, who was raised in the Church of England, is of English background; has published 17 novels and written numerous rock operas and musicals. Ronald Harwood (né Horwitz; 9 November 1934 – 8 September 2020) was a South African Jewish -born British author, playwright, and screenwriter, best known for his plays for the British stage as well as the screenplays for The Dresser (for which he was nominated for an Oscar) and The Pianist, for which he won the 2003 Academy Award for Best Adapted Screenplay. He was nominated for the Best Adapted Screenplay Oscar for The Diving Bell and the Butterfly (2007); cousin of Antony Sher.

=== Health history === A patient's health history may include disorders that affect the body's ability to heal itself. These disorders are called comorbidities and may interfere with circulatory and metabolic body functions, levels of various physiological assessment components (sugar, albumin, etc.), and induce other factors that negatively affect the healing. Common co-morbidities are: diabetes, venous insufficiency or peripheral arterial disease, respiratory and cardiovascular disorders, malignancies and autoimmune disorders.

Sources: en.wikipedia.org

Notes from published material

10 December – The Metropolitan Police confirms that Deveca Rose, a 29-year-old mother, whose four children died in a South London house fire in December 2021, has been charged with manslaughter. Rose also faces charges of child abandonment. The skull of a pliosaur has been excavated from the cliffs of Dorset's Jurassic Coast. McDonald's says it has "permanently removed" a "third party security guard" who was filmed the previous day kicking a homeless man's possessions out of the way while mopping the floor outside the food outlet's premises in Victoria Street, London. The footage gained public attention after it was posted on social media. 11 December – Following a trial at the Old Bailey, Ashana Studholme, Lisa Richardson and Shaun Pendlebury are convicted of the September 2022 murder of Shakira Spencer, a west London mother-of-two, who was tortured, starved and beaten to death by the trio. The Association of School and College Leaders (ASCL) and National Association of Head Teachers (NAHT) issue a joint statement calling for the immediate pause of Ofsted inspections following the outcome of the inquest into the death of Ruth Perry. 12 December – Nottingham City Council outlines a programme of cost savings, including the loss of 550 jobs, as it seeks to deal with a £50m deficit. At a meeting with MPs, Sir Adrian Montague, chairman of Thames Water, says that the company cannot afford to repay a £190m loan which is due in April 2024.

=== Issues of dosage quantification and standardization === As Knopp and her associates note (JK.1), a manufacturer's standard sample has its universally agreed-upon potency (i.e., its specific biological activity) precisely expressed, by convention, in international units (IU), with one international unit of insulin (1 IU) defined as the "biological equivalent" of 34.7 μg pure crystalline insulin. Yet, as they also note, there is no universally agreed-upon "conversion factor" to express the mass of that same sample in International System Units (SI).

Continuous positive airway pressure (CPAP) is effective for both moderate and severe disease. It is the most common treatment for obstructive sleep apnea. Variable positive airway pressure (VPAP) (also known as bilevel (BiPAP or BPAP)) uses an electronic circuit to monitor the patient's breathing and provides two different pressures, a higher one during inhalation and a lower pressure during exhalation. This system is more expensive and is sometimes used with patients who have other coexisting respiratory problems or who find breathing out against an increased pressure to be uncomfortable or disruptive to their sleep. Nasal EPAP, which is a bandage-like device placed over the nostrils that utilizes a person's own breathing to create positive airway pressure to prevent obstructed breathing. Automatic positive airway pressure, also known as "Auto CPAP", incorporates pressure sensors and monitors the person's breathing. A 5% reduction in weight among those with moderate to severe OSA may decrease symptoms similarly to CPAP. Encouraging people with moderate to severe OSA to use CPAP devices can be challenging, as their use often requires a behavioural change in sleeping habits. 8% of people who use CPAP devices stop using them after the first night, and 50% of people with moderate to severe OSA stop using their devices in the first year. Educational initiatives and supportive interventions to help improve compliance with CPAP therapy have been shown to improve the length of time people who need CPAP therapy use their devices.

A possible cause of incorrect urine test results is the presence of metabolites from other anabolic steroids, though modern urinalysis can usually determine the exact anabolic steroid used by analyzing the ratio of the two remaining nandrolone metabolites. As a result of the numerous overturned verdicts, the testing procedure was reviewed by UK Sport. In October 2007, three-time Olympic gold medalist for track and field Marion Jones admitted to use of the drug, and was sentenced to six months in jail for lying to a federal grand jury in 2000. Mass spectrometry is also used to detect small amounts of nandrolone in urine samples.

=== Saliva drug screen / Oral fluid-based drug screen === Saliva / oral fluid-based drug tests can generally detect use during the previous few days. It is better at detecting very recent use of a substance. THC may only be detectable for 2–24 hours in most cases. On site drug tests are allowed per the Department of Labor. Detection in saliva tests begins almost immediately upon use of the following substances, and lasts for approximately the following times:

Sources: en.wikipedia.org

Background from the literature

Unlike Half-Life however, armor takes the form of actual vests, and can not be replenished by chargers like health can. Unlike Half-Life and its expansions, Gunman Chronicles, however sparsely, uses cutscenes to tell key parts of the storyline. These usually appear only as transitions between different worlds and levels however, and thus most of the plot is seen through the eyes of the player like in Half-Life.

The epiglottis is a flap of elastic cartilage attached to the entrance of the larynx. It is covered with a mucous membrane and there are taste buds on its lingual surface which faces into the mouth. Its laryngeal surface faces into the larynx. The epiglottis functions to guard the entrance of the glottis, the opening between the vocal folds. It is normally pointed upward during breathing with its underside functioning as part of the pharynx, but during swallowing, the epiglottis folds down to a more horizontal position, with its upper side functioning as part of the pharynx. In this manner it prevents food from going into the trachea and instead directs it to the esophagus, which is behind. During swallowing, the backward motion of the tongue forces the epiglottis over the glottis' opening to prevent any food that is being swallowed from entering the larynx which leads to the lungs; the larynx is also pulled upwards to assist this process. Stimulation of the larynx by ingested matter produces a strong cough reflex in order to protect the lungs.

Hahn joined the new gas command unit at Imperial Headquarters in Berlin in December 1916 after travelling between the western and eastern front, Berlin and Leverkusen between mid-1914 and late 1916. Most of the students, laboratory assistants and technicians had been called up, so Hahn, who was stationed in Berlin between January and September 1917, and Meitner had to do everything themselves. By December 1917 she was able to isolate the substance, and after further work were able to prove that it was indeed the missing isotope. Meitner submitted her and Hahn's findings for publication in March 1918 to the scientific paper Physikalischen Zeitschrift under the title Die Muttersubstanz des Actiniums; Ein Neues Radioaktives Element von Langer Lebensdauer ("The Mother Substance of Actinium; A New Radioactive Element with a Long Lifetime"). Although Fajans and Göhring had been the first to discover the element, custom required that an element was represented by its longest-lived and most abundant isotope, and while brevium had a half-life of 1.7 minutes, Hahn and Meitner's isotope had one of 32,500 years. The name brevium no longer seemed appropriate. Fajans agreed to Meitner and Hahn naming the element "protoactinium". In June 1918, Soddy and John Cranston announced that they had extracted a sample of the isotope, but unlike Hahn and Meitner were unable to describe its characteristics. They acknowledged Hahn´s and Meitner's priority, and agreed to the name. The connection to uranium remained a mystery, as neither of the known isotopes of uranium decayed into protactinium.

=== Nordic countries === Norway was the first country in the world to outlaw beak trimming in 1974, followed by Finland in 1986 and Sweden in 1988. Beak trimming was subsequently phased out in Denmark in two stages: in 2013 for the enriched cage system and in 2014 for aviary and free range systems.

Benazepril (Lotensin) Cilazapril (Inhibace) Enalapril (Vasotec/Renitec/Berlipril/Enap/Enalapril Profarma) Imidapril (Tanatril) Lisinopril (Listril/Lopril/Novatec/Prinivil/Zestril, Lisidigal) Moexipril (Univasc) Perindopril (Coversyl/Aceon/Perindo) Quinapril (Accupril) Ramipril (Altace/Prilace/Ramace/Ramiwin/Triatec/Tritace/Ramitac) Trandolapril (Mavik/Odrik/Gopten)

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan-2?

It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.

How does it differ from melanotan-1?

Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.

Is it the same as bremelanotide?

No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.

What is melanotan II?

It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.

Network